Here are 3 exciting biotech shares at the top of my list

When it comes to biotech shares in Australia there is one in particular that stands head and shoulders above the rest.

That is of course the $61 billion giant CSL Limited (ASX: CSL). I believe CSL is one of the highest quality companies in Australia and a great buy and hold investment option.

But it’s not only biotech that I feel investors should be taking a close look at today. Here are two more exciting biotech shares on my watch list:

The Bionomics Ltd (ASX: BNO) share price has climbed around 6% year-to-date. Investors appear to be snapping up shares thanks to the positive results of its BNC210 anxiety drug’s Phase II trials. BNC210 not only outperformed the current standard of care, but also exhibited no signs of sedation, memory impairment, addiction, or loss of motor co-ordination. Whilst it is still early days, if BNC210 lives up to its potential then investors will be rewarded handsomely. Management estimates the global therapeutic market for the treatment of anxiety to be worth US$18.2 billion by 2020.

The Cynata Therapeutics Ltd (ASX: CYP) share price has jumped almost 12% this week thanks to a research note out of Shaw and Partners which rated the regenerative medicine company as a buy with a $1.20 price target. It’s not hard to see why its analysts are bullish. Cynata’s Cymerus technology can produce an unlimited number of high quality stem cells at a low cost. These can then be used to treat numerous diseases including Graft versus Host Disease (GvHD) and cardiovascular disease. Japanese giant FUJIFILM sees a lot of potential in Cynata and recently bought a 10% stake in the company. As part of the arrangement it has the option to an exclusive worldwide license to market and sell its therapeutic MSC product CYP-001 for the treatment of GvHD. Cynata is definitely worth taking a closer look at today in my opinion.

Finally, if biotech shares are too high risk for your liking then I would suggest you take a look at these high-flying growth shares. I'm tipping each of them for big things this year.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.